UK - GlaxoSmithKline is to make substantial changes to its board of executives following sustained pressure from pension fund investors.
The NAPF and the Association of British Insurers have been staunch critics of GSK’s remuneration policies – principally in relation to its chief executive officer Jean-Pierre Garnier, who was looki...
To continue reading this article...
Join Professional Pensions
- Unlimited access to real-time news, analysis and opinion from the industry
- Receive our in-depth monthly magazine in either print or digital format
- Access our Sustainable Investment Hub covering news and opinion from thought leaders in the ESG space
- Receive important and breaking news stories selected by the Editors in our daily newsletter
- Hear from industry experts and other forward-thinking leaders
- Receive a monthly members-only newsletter with exclusive opinion pieces from leading industry experts and a feature from the magazine in advance of its release date